Tardive dyskinesia (TD) …

Olga Waln MD

Movement Disorders

Updated 06.19.2024
Released 11.23.1993
Expires For CME 06.19.2027

Tardive dyskinesia

Author: Olga Waln MD

See Contributor Disclosures

Editor: Robert Fekete MD

Tardive dyskinesia

In This Article

Quick Link

Introduction

Overview

Tardive dyskinesia is a group of delayed-onset iatrogenic movement disorders caused by dopamine receptor-blocking medications that can manifest as orobuccolingual stereotypy, dystonia, akathisia, tics, tremor, chorea, or as a combination of different involuntary movements. Abnormal movements can persist for years despite discontinuation of the offending drug. In many cases, tardive dyskinesia can be an irreversible condition, resistant to pharmacological treatment. Awareness of offending agents and early recognition of tardive dyskinesia is, therefore, important in clinical practice. This article presents an overview of the etiology and phenomenology of tardive dyskinesia, as well as the current views on pathophysiology and treatment of tardive dyskinesia.

Key points

	• Tardive dyskinesia usually occurs after prolonged exposure to medications with dopamine receptor-blocking properties and may emerge during the course of treatment or following discontinuation of the medication or reduction of the dose.
	• Tardive dyskinesia may not improve, despite discontinuation of the offending agent.
	• The pathophysiology of tardive dyskinesia remains poorly understood.
	• Gradual tapering off an offending drug and/or the use of VMAT are currently the main treatment strategies for tardive dyskinesia.

Historical note and terminology

Neuroleptics were introduced in 1952 for treatment of schizophrenia, and the first case of drug-induced orofacial-lingual stereotypy, referred to as “paroxysmal dyskinesia,” was reported five years later (131). Unlike acute drug-induced movement disorders (acute dystonic reaction) or dose-dependent reversible conditions (drug-induced parkinsonism) that subside with discontinuation of the medication, other hyperkinetic movement disorders can have delayed onset for months or years after the initial dose, hence, the name “tardive.” The term "tardive dyskinesia" was first introduced in 1964 and is now commonly used to identify any tardive movement disorder, including stereotypy, akathisia, dystonia, myoclonus, tics, chorea, and tremor (36). Frequently, however, clinicians reserve the term “tardive dyskinesia” or “classic tardive dyskinesia” when referring to orofacial-lingual stereotypy, and they use the term “tardive syndrome” for all tardive movement disorders, especially those cases manifesting as a combination of a few different abnormal movements. The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V), defines tardive dyskinesia as “involuntary athetoid or choreiform movements lasting at least a few weeks, developing in association with the use of a neuroleptic medication for at least a few months, and persisting beyond 4-8 weeks” (05). However, this definition fails to identify other nonneuroleptic agents that can cause tardive dyskinesia, or to include all phenomenological presentations of tardive syndrome.

Clinical manifestations

Presentation and course

	• Tardive dyskinesia symptoms usually manifest a few months after continuous treatment with an offending drug.
	• Tardive dyskinesia can appear following sudden discontinuation or dose reduction of a dopamine-receptor blocking medication.
	• Tardive syndrome can manifest as an isolated movement disorder (stereotypy, dystonia, akathisia) or as a combination of many phenomenologically different movements.
	• Orofacial stereotypies are most common presentation of tardive syndrome.

Tardive dyskinesia can manifest as early as three months after continuous treatment with a dopamine-blocking medication (or one month in elderly patients); however, in the majority of cases it occurs one to two years after the beginning of treatment (04; 156). Reduction of the dose or sudden discontinuation of the offending drug can also cause tardive syndrome within four weeks for oral or eight weeks for depot medication. Tardive dyskinesia has insidious onset, with the symptoms usually evolving over a few weeks.

Tardive syndrome is a group of phenomenologically different involuntary movements manifesting as orobuccolingual stereotypy, dystonia, akathisia, tics, tremor, myoclonus, chorea, or a combination of a few types of abnormal movements (44; 129). A stereotypy is an involuntary, patterned, repetitive, continuous, coordinated, purposeless, or ritualistic movement.

Classic tardive dyskinesia. Classic tardive dyskinesia manifests as orobuccolingual stereotypy involving the tongue, lips, and jaw and producing repetitive licking, lip smacking, and chewing movements (64; 156). There may be torsional movements of the tongue inside of the mouth, quick tongue protrusions (flycatcher tongue), or pushing of the tongue against the inner cheek creating a bulge (bonbon sign). Facial movements are typically limited to the lower face, less frequently involving the forehead.

Tardive dyskinesia associated with paroxetine use

This woman developed classic orofacial stereotypy while on paroxetine. In addition, she displays rhythmic stereotypy of her trunk. When standing, she displays a "walking in place" stereotypy. (Contributed by Dr. Joseph Jankovic.)

In contrast to idiopathic craniocervical dystonia (which consists of blepharospasm and cervical dystonia), lip pursing, lip smacking, and facial grimacing are more likely to be found associated with tardive dyskinesia (146). Other characteristically (though less commonly) affected areas include the respiratory muscles, causing erratic breathing, stridor, and respiratory noises such as humming or moaning (166).

Tardive orofacial and respiratory stereotypies helped by tetrabenazine

This woman displays orofacial and respiratory tardive stereotypy. She improved markedly with tetrabenazine. (Contributed by Dr. Joseph Jankovic.)

Besides orobuccolingual stereotypy of classic tardive dyskinesia, some patients have limb and trunk stereotypy manifesting as repetitive flexion and extension of the fingers and toes, tapping of the foot while sitting, flexion and extension of the thighs when supine, rocking, swaying trunk movements, and thrusting pelvic movements (38; 137). The repetitive, patterned, seemingly purposeful nature of the movements in tardive dyskinesia often resembling ritualistic gestures of mannerism has led to their designation as "stereotypies" (142). This can be contrasted to the choreiform movements seen in Huntington disease wherein the movements are random and unpredictable (139).

Involuntary movements in tardive dyskinesia are often suppressible by voluntary actions involving the affected part. Many patients are unaware of their tardive dyskinesia (24), but others with severe orolingual dyskinesias experience difficulty with eating and talking and have dental damage, along with embarrassment. Generalized dyskinesias may lead to respiratory difficulties, dysphagia, and gait and balance impairment leading to falls. Changes in gait can be described as “dance-like” (repetitive short steps on toes followed by long stride) or “duck-like” (wide-based gait with short stride length and mild steppage features), broad-based, spastic, or generally unsteady (84).

Tardive dystonia typically manifests as retrocollis with truncal backward arching or scoliosis, internal rotation and adduction of the arms, extension of the elbows, and flexion of the wrists (14; 156). A tardive Pisa syndrome, a lateral flexion of the trunk, has been reported in a young patient treated with aripiprazole (30). Focal tardive dystonia can affect facial muscles, tongue, jaw, or cervical muscles.

Tardive akathisia refers to an inner sense of restlessness and inability to sit still (94). Patients may have associated repetitive movements and vocalizations resembling tardive stereotypy such as body rocking, crossing and uncrossing of the legs, rubbing the scalp, marching in place, and moaning. However, tardive akathisia has a sensory component of internal restlessness whereas tardive stereotypy does not. In addition to a generalized sense of restlessness, there may be focal symptoms described as a burning sensation, most commonly in the oral and genital areas (40). Indeed, sensory aspects of tardive dyskinesia, which include tardive akathisia, are increasingly recognized in many movement disorders (122).

Other tardive syndromes include tardive tics, tardive myoclonus, tardive chorea, and tardive tremor phenomenologically resembling hyperkinetic movement disorders not caused by the dopamine-blocking agents (146; 151; 41; 156).

Withdrawal emergent syndrome is a rare condition described in children following sudden discontinuation a dopamine-blocking agent. It manifests as generalized chorea, usually sparing the face, days or weeks after withdrawal of the offending drug and self-limiting within a few weeks (106).

Prognosis and complications

In the majority of patients, tardive dyskinesia persists for years or decades even following discontinuation of the offending medication. In many cases it can be irreversible. Rate of remission after eliminating a dopamine-blocking medication (or in rare cases even while continuing treatment) varies widely in the literature, from 2.5% per year for patients still on a suspected offending agent up to 33% two years after stopping a drug (72; 149). Likelihood of remission increases if dopamine receptor antagonists are withheld earlier in the course of tardive dyskinesia, whereas a longer exposure to the drugs is associated with worse prognosis. The majority of remissions occur within one year of drug discontinuation, but persistence of movements for up to 5 years may still be followed by complete spontaneous resolution (79). Once established, tardive dyskinesia does not tend to continue to progress in severity; however, the course can be waxing and waning.

Clinical vignette

A 79-year-old woman with chronic low back pain complained to her physician of insomnia. She was treated with haloperidol, amitriptyline, and zolpidem for about five years. In the past two months, she began having involuntary movements of her mouth, which progressed from the onset until her speech became dysarthric. Examination at that time showed “constant mouth movements,” and the haloperidol was discontinued. She returned to the original physician three months later, and haloperidol was restarted for unclear reasons. She soon developed “shaking” of her head and feet and dysphagia. The haloperidol was stopped again after one month. Treatment with anticholinergics, botulinum toxin injections, and diazepam yielded little or no benefit.

On examination 15 months after onset of the involuntary movements, there were continuous orofacial dyskinesias. Alternating protrusion and retraction of the tongue at rest were diminished by active tongue protrusion. Chewing movements of the jaws were abolished by voluntary mouth opening. There was intermittent gentle flexion and extension of the neck, and mild rocking of the trunk when standing. There were dyskinesias of the feet (greater on the right) and slight dyskinesias of the left upper limb as well.

Tardive dyskinesia

There are continuous orolingual dyskinesias, consisting mainly of chewing movements and alternating tongue protrusion and retraction. Holding the jaws open abolishes the chewing but not the tongue movements. Active protrusion of t...

Biological basis

Etiology and pathogenesis

	• First-generation neuroleptics have high D2 receptor occupancy and, therefore, higher risk of causing tardive dyskinesia.
	• Chronic blockade of dopamine receptors leading to receptor upregulation and increased receptor sensitivity are believed to be the main pathophysiological mechanisms of tardive dyskinesia.
	• Oxidative stress likely plays an important role in the pathogenesis of tardive dyskinesia.
	• Many gene candidates associated with tardive dyskinesia were identified.

Tardive dyskinesia occurs as a result of chronic exposure to dopamine receptor-blocking agents, drugs used mainly to treat psychiatric or gastrointestinal disorders (156). Due to their high D2 receptor occupancy, the first generation, or typical, neuroleptics carry greater risk than second- or third-generation neuroleptics, which are often referred to as atypical (31). The latter medications have low D2 receptor occupancy, and hierarchical risk of causing tardive dyskinesia from least to greatest is as follows. Clozapine has a lower risk than quetiapine, which has a lower risk than olanzapine and ziprasidone; risperidone carries a lower risk than the last two at low doses, but with increased risk at higher doses (150). Despite a low prevalence of extrapyramidal symptoms, newer atypical neuroleptics, such as aripiprazole, have been reported to cause tardive dyskinesia (100; 125; 134). Essentially all atypical neuroleptics have been documented to cause tardive dyskinesia (77).

Although historically neuroleptics were to blame for most cases of tardive dyskinesia, metoclopramide is a common reported cause (121). Since approval by the Food and Drug Administration in 1979, metoclopramide has become one of the most widely used drugs for gastrointestinal motility disorders. One of the major advantages of metoclopramide is that it acts centrally as an antiemetic, antagonizing dopamine receptors in the chemoreceptor trigger zone, and peripherally as a prokinetic drug. Several studies have indicated that metoclopramide usage often continues despite the development of tardive dyskinesia (45). In a study, the average duration of exposure to metoclopramide before onset of hyperkinesia was 12 months and therapy was continued for an average of 6 months after symptom onset (109). Metoclopramide and other antiemetics with dopamine receptor blocking properties such as prochlorperazine are also used to treat migraine, and carry the risk of causing tardive dyskinesia (162).

Rare cases of tardive dyskinesia-like syndrome have been reported as a result of long-term treatment with antidepressants, including selective serotonin and norepinephrine reuptake inhibitors and tricyclics, or lithium (49; 22; 100; 02). Calcium channel blockers (flunarizine, cinnarizine) are also associated with tardive dyskinesia in some countries (32). The topic of tardive dyskinesia caused by non-dopamine blocking drugs remains open for debate. Some clinicians and scientists believe that non-dopamine blocking drugs are unlikely causative agents in tardive dyskinesia but they rather provide a “priming” effect that can unmask or exacerbate dyskinesia in patients who have been exposed to dopamine-blocking drugs, even in the remote past (29).

The pathophysiology of tardive dyskinesia remains poorly understood. A number of lines of evidence point to the involvement of dopaminergic systems in the pathogenesis of tardive dyskinesia (156; 12). Experimental animals chronically exposed to antipsychotics demonstrate behavioral supersensitivity to dopamine agonists and increased striatal dopamine binding (80). In a rat model of haloperidol-induced oral dyskinesias, the severity of dyskinesia was correlated with degenerative changes in substantia nigra cells (11). The long-term use of antipsychotics has been associated with a 3-fold reduction in density of striatal dopamine terminals in patients with tardive dyskinesia, but not in individuals who had no tardive dyskinesia as measured by imaging of dopamine transporters (133). This increased loss of striatal terminals was attributed to accumulation of antipsychotics in the neuromelanin of the substantia nigra. PET studies in humans implicate D2 receptor upregulation in the generation of tardive dyskinesia (138).

The weight of evidence favors the notion that chronic blockade of D2 and possibly D3 dopamine receptors leads to receptor upregulation and increased receptor sensitivity. Primate studies indicated that upregulated striatal D3 rather than D2 receptors correlate with the development of tardive dyskinesia (97; 58). Yet it is not clear how this leads to the development of a chronic hyperkinetic movement disorder not remitting even after discontinuation of a causative medication, or why only a minority of people with similar drug exposure develop the syndrome. One widely studied mechanism invoked to explain these gaps in our knowledge is the ubiquitous “oxidative stress” hypothesis (83). Evidence of a role for oxidative stress in the pathogenesis of tardive dyskinesia comes in several forms. Tardive dyskinesia patients have been shown to have elevated plasma activity of manganese superoxide dismutase compared to schizophrenics without tardive dyskinesia and normal controls, and the level of activity is correlated with the clinical severity of dyskinesia (172). The same investigators have found that a polymorphism of the superoxide dismutase gene interacts with a polymorphism of the dopamine D3 receptor gene to produce an increased susceptibility to development of tardive dyskinesia (173). A study demonstrated lower levels of manganese superoxide dismutase in schizophrenic patients with tardive dyskinesia compared to those without (164). A rodent study found that haloperidol led to an increase in vacuous chewing movements and an increase in S100B (a potential biomarker of structural brain damage) in the prefrontal cortex, striatum, substantia nigra, and globus pallidum (08). Treatment with antioxidants gingko biloba leaf extract (EGb761) or vitamin E was associated with a decrease in abnormal movements and a decrease in S100B expression. However, a study of the effect of another antioxidant lipoic acid on haloperidol-induced vacuous chewing movements in rats reported only nonsignificant decreases of movement on lower doses of lipoic acid, but significant worsening of dyskinesia on higher doses of lipoic acid (93).

Alternative theories regarding the pathophysiology of tardive dyskinesia exist (21; 12). One hypothesis relates tardive dyskinesia to a GABAergic hypofunction and degeneration of GABAergic interneurons regulating balance between direct and indirect basal ganglia pathways (50). Opioid pathways and excessive production of neurotensin may be involved (101; 102). A preliminary report on proton magnetic resonance spectroscopy in patients with and without tardive dyskinesia suggests that the latter is associated with accentuation of metabolic abnormalities, reflected by increased choline/creatinine ratios, in the basal ganglia found in schizophrenia (10). Several animal and human studies provide evidence that chronic use of antipsychotics may result in structural changes in brain with neuronal loss and gliosis in basal ganglia (78; 60). Structural changes in cerebral cortex with decreased gray matter volume in cuneus and lingual gyri on MRI were reported in schizophrenic subjects with tardive dyskinesia versus schizophrenics without tardive dyskinesia or healthy controls (167). Degree of gray matter volume loss in those two areas correlated with severity of tardive dyskinesia on AIMS (Abnormal Involuntary Movement Scale). Some studies have shown that serum levels of brain-derived neurotrophic factor (BDNF), which protects against neuronal damage in the nigrostriatal dopaminergic system, are lower in patients with tardive dyskinesia than those without (147; 171). Immune dysregulation is a proposed mechanism underlying tardive dyskinesia. Alterations of the levels of IL-2, IL-6, and IL-8 were associated with schizophrenia patients with tardive dyskinesia compared to those without and normal controls (07). The role that these changes play in the development of tardive dyskinesia is unclear. A maladaptive NMDA-medicated synaptic plasticity hypothesis suggests that dopamine-receptor hypersensitivity and neurodegenerative changes due to oxidative stress caused by chronic exposure to dopamine-blocking medications can alter synaptic plasticity and lead to a formation of miscoded motor programs and abnormal hyperkinetic movements (152).

The majority of patients on similar drug regimens do not develop tardive dyskinesia, and those affected vary considerably in the severity of the movements. Unaffected siblings of schizophrenic patients with tardive dyskinesia have a higher prevalence of spontaneous dyskinesias than patients without siblings with tardive dyskinesia (103). Thus, individual susceptibility plays a large role, and this may have a genetic basis (83). Gene candidates include those coding for dopamine D2 and D3 receptors, serotonin 5HT2A receptors, catechol-O-methyltransferase (COMT) enzyme, manganese superoxide dismutase, and CYP2D6. Findings from genetic studies have reported on certain polymorphisms such as CYP2D6*10, DRD2 Taq1A, DRD3 Ser9Gly, HTR2A T102C, and MnSOD Ala9Val, although these results remain controversial (86). Furthermore, genome-wide association studies have identified genes associated with tardive dyskinesia such as rs7669317 on 4q24, GLI2 gene, GABA pathway genes, and HSPG2 gene (86). Several studies have implicated polymorphisms in exon 1 of the dopamine D3 receptor gene and the 5-HT2A receptor gene (145; 89). One report supports the role of COMT and dopamine D3 receptor genes in a population of schizophrenics in North India (141). However, a review of 11 case-control studies did not find significant association between COMT Val158Met gene polymorphism and risk of tardive dyskinesia (96). In Caucasians, but not African Americans, the APOE2 allele may increase the risk of developing tardive dyskinesia (53). In a study of 491 Caucasian patients with schizophrenia, a significant association was found between the functional mutation N251S-polymorphism of the PIP5K2A gene (rs10828317) and tardive dyskinesia (37). A mutation in this gene that codes for phosphatidylinositol-4-phosphate-5-kinase type IIa suggests a role of this kinase in tardive dyskinesia and neurotoxicity. In a genome-wide association study of 505 patients with paranoid schizophrenia, 95 patients had tardive dyskinesia, and 503 healthy controls revealed that paranoid schizophrenia and orofacial dyskinesia were associated with the genomic loci on chromosomes 3p22.2, 8q21.13, and 13q14.2 (91). A review of 43 animal studies of tardive dyskinesia pathogenesis identified eight genes that also reached statistical significance in at least one clinical study (153). Gene candidates include variants of SLC18A2 gene encoding for vesicular monoamine transporter 2 protein (VMAT2); dopamine receptor genes DRD1, rs4532, and DRD3 rs6280 polymorphisms; serotonin receptor gene HTR2A gene variants; NMDA glutamate receptor genes GRIN2A and GRIN2B variants; oxidative stress-related gene SOD2 rs4880 variant; and CYP2D6 variants leading to decreased metabolizing capacity of the enzyme). Pharmacogenomic studies have produced conflicting results regarding the association of genetic polymorphisms with tardive dyskinesia, and they deserve further study (23; 95).

Epidemiology

	• Up to 20% of patients treated with neuroleptics can develop tardive dyskinesia.
	• Patients more vulnerable to developing tardive dyskinesia are older women and patients with previous brain damage, preexisting drug-induced parkinsonism, and greater total drug exposure.

Reported incidence and prevalence rates of tardive dyskinesia vary widely, depending on the population, study design, and diagnostic criteria used. A review of 56 prevalence studies found that an average of 20% of 34,555 neuroleptic-treated patients demonstrated involuntary movements compatible with tardive dyskinesia (71). The cumulative incidence increases for the first five years of treatment; the prevalence subsequently tends to remain stable as remission rates equalize with incidence rates (48). A prospective study of schizophrenics suffering their first episode of psychosis and treated with haloperidol found an incidence of tardive dyskinesia of 12.3% in the first 12 months (118). Meta-analysis of 57 randomized controlled studies including 32 first-generation antipsychotics arm and 86 second-generation antipsychotics arm reported annualized incidence of tardive dyskinesia of 6.5% in the former arm versus 2.6% in the latter arm (19). A systematic review of studies from 1957 to 2015 estimated that the incidence of probable tardive dyskinesia was 23% for patients treated with first-generation typical neuroleptics versus 7% for patients using second-generation neuroleptics at one year (114). The prevalence of tardive dyskinesia in patients treated with metoclopramide ranges from 1% to 10% in different studies (127).

A retrospective study of 123 patients treated with antipsychotics for more than six months in an outpatient psychiatric clinic (96.8% had schizophrenia, 66.7% were women, mean age 45.6 years) reported 35 patients with at least one episode of a tardive syndrome (87). The prevalence of the various phenomenologies of tardive syndromes included 21.1% tardive dyskinesia, 12.5% tardive dystonia, 2.4% tardive tremor, and 2.4% tardive akathisia. The term “tardive dyskinesia” in this study was presumably used to describe the classic orofacial stereotypy.

Prevalence rates for tardive dyskinesia increase with age due to a higher incidence and a lower remission rate in older patients. Older patients may have difficulty metabolizing the medication and may be more susceptible to side effects (99). Older women appear to be the most vulnerable group (112). Younger men have a greater risk of developing tardive dystonia. The prevalence in children and adolescents is distinctly lower, but tardive dyskinesia and withdrawal emergence syndrome are increasingly recognized in children and even infants (27; 105; 106). In a 1-year, multicenter observational study in a pediatric population of 265 subjects exposed to antipsychotics, 5.8% developed tardive dyskinesia at follow-up (46). In this study, younger age, longer exposure to antipsychotics, and a history of psychotic symptoms were associated with an increased risk of tardive dyskinesia. Other proposed risk factors in adults include a greater total drug exposure, preexisting drug-induced parkinsonism, treatment for an affective rather than a psychotic disorder, alcoholism, previous brain damage, and smoking (67; 25). A study of 77,022 adult inpatient admissions for mood disorders and schizophrenia with secondary diagnosis of tardive dyskinesia and age-matched controls without tardive dyskinesia found that most tardive dyskinesia patients were older (50-64 years; 40%), with nearly equal proportions of men and women (123). African Americans had 2-fold higher odds of tardive dyskinesia. Higher likelihood for cardiometabolic comorbidities—obesity (OR 1.61, 95% CI 1.481-1.756), hypertension (OR 1.78, 95% CI 1.635-1.930), and diabetes (OR 1.54, 95% CI 1.414-1.680)—compared to controls were reported.

Management

	• Gradual weaning off a causative drug, switching to an atypical neuroleptic, or at least a dose reduction are considered the first step in treatment of tardive dyskinesia.
	• Vesicular monoamine transporter 2 inhibitors are currently considered the most effective pharmacological treatment options for tardive dyskinesia, even for patients still taking neuroleptics.
	• Anticholinergic medications are not recommended for prevention or treatment of tardive dyskinesia.

The development of tardive dyskinesia should prompt a reevaluation of the necessity for the causative agent. This is particularly true when a dopamine receptor-blocking drug is being used for a nonpsychotic indication. An attempt should be made to reduce the dose of the offending drug if it cannot be withdrawn entirely. Many patients will not improve despite discontinuation of their medication, whereas others may have spontaneous resolution of their movements while continuing to take the responsible drug at the same dose. However, it is widely believed that a patient's best chance for a remission lies with cessation of exposure to the offending agent. Before embarking on this course, it is important with psychiatric patients to weigh the potential benefit of improving tardive dyskinesia, often unnoticed by patients, against the risk of relapse of psychotic symptoms (104). For patients with mild tardive dyskinesia who are not distressed by the symptoms, slow tapering off an offending drug followed by watchful observation may be a reasonable management option. Those who cannot discontinue taking antipsychotic medication can be candidates for therapy with clozapine or quetiapine, atypical dopamine receptor antagonists that rarely cause tardive dyskinesia. A study of 35 patients with schizophrenia or bipolar disorder who switched to clozapine from another antipsychotic drug after developing tardive dyskinesia reported remission of symptoms in 65.7% of patients, especially those of younger age and with milder tardive dyskinesia (85). Meta-analysis of 48 studies (including 13 clinical trials and 35 case reports) reported significant improvement of tardive dyskinesia symptoms in 86.7% of clozapine-treated patients with schizophrenia spectrum disorders (average dose of clozapine = 355 mg/day) and 93% of patients with other psychiatric disorders (average dose of clozapine = 152.5 mg/day) (163). Although potentially life-threatening, agranulocytosis occurs in about 0.8% to 3% of patients treated with clozapine; therefore, close monitoring of white blood cell counts is required (82; 03).

A wide variety of pharmacologic agents has been reported to lessen the involuntary movements, but may produce only modest benefit (148). Increasing the dose of a dopamine receptor antagonist can acutely improve tardive dyskinesia, but this maneuver may contribute to a more firmly entrenched movement disorder over the long term. Therefore, it is useful only if immediate control of the severe dyskinesia is imperative. An evidence-based guideline for the treatment of tardive syndromes was published by the American Academy of Neurology in 2013 (15). Based on the available evidence, clonazepam and ginkgo biloba were found to probably improve tardive syndromes (level B), and amantadine and tetrabenazine might also be effective (level C).

In small scale studies, tetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor (which in 2008 was FDA approved for treating Huntington disease in the United States), has been shown to be an effective medication for the treatment of tardive dyskinesia (65; 117; 74; 35; 66; 68; 63). However, dopamine depleters may cause drug-induced parkinsonism, akathisia, depression, and excessive daytime drowsiness. There has only been one published report of tardive dyskinesia caused by tetrabenazine (92). The author describes oral-buccal-lingual movements and chorea of the hands and feet in a 55-year-old man treated with tetrabenazine 12.5 mg twice daily for cervical dystonia. The movements resolved after discontinuation of the medication. Although tetrabenazine has been implicated in this man’s movement disorder, it should be noted that he was treated for his underlying depression with paroxetine for 10 years, and later with desvenlafaxine until the onset of the dyskinesia. It is, therefore, possible that the selective serotonin reuptake inhibitors have caused or contributed to the tardive dyskinesia (88). Selective VMAT2 inhibitors (deutetrabenazine and valbenazine) were approved by the FDA in 2017 for the treatment of tardive dyskinesia, and they exhibited at least the same effectiveness as tetrabenazine, but with a better side effect profile (63; 132). Bhidayasiri and colleagues consider deutetrabenazine and valbenazine effective treatments of tardive dyskinesia (level A) that must be recommended to patients (63; 16; 113). Clinical trials of both medications in tardive dyskinesia reported significant improvement of AIMS scores and favorable safety profiles with low rates of serious side effects, specifically QT prolongation, parkinsonism, and suicidality (51). Valbenazine, a purified (+)-α-isomer of tetrabenazine that also acts as a VMAT2 inhibitor, was evaluated in a 6-week, randomized, double-blind, placebo-controlled study involving 102 subjects with moderate to severe tardive dyskinesia (115). There was a significant reduction in the AIMS scores with NBI-98854 compared to placebo (mean change -3.6 vs. -1.1, p < 0.0005). The most common side effects were fatigue and headache. A phase 3 (KINECT 3) study concluded that a once-daily administration of 40 or 80 mg of valbenazine provided significant improvement in tardive dyskinesia versus placebo (mean AIMS scores change from baseline -3.2 vs. -0.1 for 80 mg dose and -1.9 vs. -0.1 for 40 mg dose) (57). Medication was generally well tolerated, even in patients taking a wide range of concomitant medications (including antipsychotic agents). A phase 3, one year, open-label trial of valbenazine (KINECT 4) reported similar data on the safety and efficacy of the medication (98). Deutetrabenazine, a reversible VMAT2 inhibitor, is a deuterated formulation of tetrabenazine. The percentage of responders in the fixed-dose phase 3 study was 46% for deutetrabenazine versus 26% for placebo on the clinical global impression of change, and an improvement in AIMS severity score of 50% or more was 34% for the deutetrabenazine arm versus 12% for placebo (26; 113). A long-term open-label study of deutetrabenazine estimated the mean change in AIMS score -4.9 at week 54, -6.3 at week 80, and -5.1 at week 106 (39). A 3-year, single-arm, open-label extension study of 343 patients with tardive dyskinesia treated with deutetrabenazine (mean dose: 39.4 ± 0.83 mg/day) reported mean change from baseline in total motor AIMS score of 6.6 ± 0.37 at week 145 (56). Two thirds of patients achieved at least 50% improvement in total motor AIMS score. Deutetrabenazine was generally well tolerated, with low rates of mild-to-moderate adverse events. Safety data of deutetrabenazine were integrated from two 12-week pivotal studies and through week 15 of the open-label extension in 384 patients with tardive dyskinesia (43). Medication was generally well tolerated with common side effects (occurred in 4% or more) including headaches, somnolence, nausea, anxiety, dry mouth, diarrhea, and insomnia. Serious side effects including depression, suicidality/self-injury, akathisia, parkinsonism, and QT prolongation were reported in 2.8% to 8.3% of patients on different doses of deutetrabenazine compared to 6.9% in placebo group. Deutetrabenazine is now available as once-daily extended release tablets and twice-daily tablets. Both formulations were found to be bioequivalent at steady state (144).

A new compound, 9-trifluoroethoxy-dihydrotetrabenazine, was identified as a promising agent for treatment of tardive dyskinesia due to its stronger, faster, and longer-lasting inhibitory effect on VMAT2 than valbenazine at an equivalent dose in rats (158).

Reserpine, another dopamine depleter, has been shown to be effective in the treatment of tardive dyskinesia, but because of its peripheral side effects such as orthostatic hypotension and lack of availability, it is almost never used (61; 34). Alpha-methylparatyrosine, a competitive inhibitor of tyrosine hydroxylase, can be effective when used with other presynaptic medications (34). A small double-blind, placebo-controlled study showed improvement of tardive dyskinesia with amantadine (120). Other drugs have been suggested as possibly being useful in treating tardive dyskinesias, including propranolol, levetiracetam, clonidine, and benzodiazepines (76). Propranolol has been reported to be effective for tardive dyskinesia in open-label studies and case series with doses less than 80 mg/day (33; 55). Vitamin E reduced Abnormal Involuntary Movement Scale (AIMS) scores by more than 40% in a double-blind study (170). A metaanalysis of 21 randomized controlled studies including 854 patients with tardive dyskinesia reported decrease of 2.36 in the AIMS score after vitamin E treatment compared to the control group (165). Vitamin B6 (110), a combination of acetazolamide and thiamine (28), verapamil (119), melatonin (136), gabapentin (54), and donepezil (20; 13) all may help, but at this time they are not established and not considered standard treatments. A Cochrane review of the studies of pyridoxal 5 phosphate (vitamin B6 or pyridoxine or pyridoxal phosphate) for the treatment of tardive dyskinesia found weak evidence for improvement in tardive dyskinesia (01). In an open-label study with eight patients, levetiracetam reduced abnormal movements (as judged on the AIMS) by 44% (81). Anticholinergics may exacerbate tardive orofacial dyskinesias and should not be used as treatment. There is no evidence that anticholinergics have an effect in preventing tardive dyskinesia, drug-induced parkinsonism, or akathisia (154). Besides, patients with higher risk of developing tardive dyskinesia and drug-induced parkinsonism are usually older and more susceptible to cognitive impairment. Therefore, prophylactic use of anticholinergics in patents on dopamine-receptor blocking medications should be avoided. Anticholinergics and baclofen, however, can be beneficial for treatment of tardive dystonia (73). There is also evidence supporting prophylactic use of anticholinergics for prevention of acute dystonia in at-risk individuals (young, males, on high-potency first generation antipsychotics) (06; 154). An open-label study involving 11 subjects with tardive dyskinesia demonstrated that add-on zonisamide (50 to 100 mg/day) significantly decreased Abnormal Involuntary Movement Scale (AIMS), and 36% of subjects had a 20% or greater improvement on AIMS (62). A randomized, double-blind, placebo-controlled trial involving 157 subjects with schizophrenia evaluated the efficacy of the antioxidant EGb-761 (extract of Ginkgo biloba) in tardive dyskinesia (169). Compared to placebo, Ginkgo biloba significantly reduced AIMS. Naringin, a bioflavonoid found in citrus fruits and thought to have potent antioxidative, anti-inflammatory, antiapoptotic, and neuroprotective properties, was evaluated as a potential protective agent against haloperidol-induced orofacial dyskinesia in rats (159). Coadministration of naringin with haloperidol significantly prevented orofacial dyskinesia. Additionally, naringin-treated animals demonstrated decreased markers of haloperidol-induced nitric oxide and lipid peroxide production as well as neuroinflammatory and apoptotic markers, but increased the antioxidation power and neurotransmitter levels in the striatum. Treatment with isoflavones, a subclass of flavonoids found mainly in soy, was able to reduce the number of vacuous chewing movements in rats when co-administered with haloperidol (108). Rats co-treated with isoflavones also had lower levels of proinflammatory cytokines compared to animals treated only with haloperidol. Other herbal antioxidants were reported to be effective in the treatment of tardive dyskinesia in animal and small human studies or case series, including crocin (carotenoid constituent of saffron), curcumin (principal substance in turmeric), rice bran oil, and Harpagophytum procumbens (grapple plant) (17; 70; 128; 130). Animal studies of nicotine and drugs targeting nicotinic acetylcholine receptors have also shown a reduction in tardive dyskinesia (124; 18). Of the different forms of tardive dyskinesia, tardive akathisia is the most difficult to treat, but in some cases, zolpidem may be helpful without causing daytime drowsiness (157).

In addition to oral medications, injections of botulinum toxin may be helpful for certain forms of tardive dyskinesia, particularly tardive dystonia but also orofacial stereotypy and lingual dyskinesia (155; 09).

Pallidotomy (160) and thalamotomy (59) have ameliorated orolinguofacial tardive dyskinesia in patients treated for severe tardive dystonia. Deep brain stimulation largely replaced stereotactical ablation surgeries, and it can be effective for medically refractive tardive dystonia according to a number of small studies and case reports (107; 42; 111). A metaanalyis of 14 studies with total of 134 patients with tardive dystonia reported 66.88 ± 11.96% overall estimate improvement in the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) after pallidal deep brain stimulation, whereas only seven patients had worsening or lack of improvement after surgery (52). Nineteen patients with tardive dyskinesia treated with bilateral globus pallidus deep brain stimulation were followed for one year, and 14 patients were followed for up to 11 years (6 to 11 years) after surgery (126). A greater than 40% reduction in the Extrapyramidal Symptoms Rating Scale (ESPS) was reported at six months follow-up, 58% reduction at 12 months, and 60% long-term reduction. Two case series reported a successful treatment of tardive dyskinesia and tardive dystonia with subthalamic deep brain stimulation (168; 143). Deep brain stimulation, however, is an off-label use for tardive dyskinesia. A placebo-controlled study of repetitive transcranial magnetic stimulation (rTMS) in 26 subjects with tardive dyskinesia reported improvement of dyskinesia with AIMS score reduction by 8.3 +/- 1.7 points in rTMS arm versus only 1.2 +/- 3.3 points in the placebo arm (75).

Outcomes

Although treatments listed above can be beneficial, all have the potential for side effects (90), and we will discuss a few. Potential side effects of tetrabenazine include sedation, depression, akathisia, parkinsonism, and QT prolongation (66). Similar but milder and less frequent side effects were reported with the use of deutetrabenazine and valbenazine. Botulinum toxin, which is used effectively to treat focal dystonia, can cause excessive weakness of targeted muscles. Potential complications of deep brain stimulation include lead misplacement, intracerebral hemorrhage, hardware malfunction, infection, stimulation-related side effects, and although uncommon, suicide (42). Thus, deep brain stimulation should be reserved for patients who have failed alternate therapies.

Media

References

01: Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2015;4:CD010501. PMID 25866243
02: Akkus M. A case of dose-dependent lithium-induced tardive dyskinesia. J Affect Disord 2022;299:205-6. PMID 34871639
03: Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329(3):162-7. PMID 8515788
04: American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text revision. Washington, DC: American Psychiatric Association, 2000:803-5.
05: American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. Arlington, VA: American Psychiatric Association, 2013:712.
06: American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 3rd edition. Washington, DC: American Psychiatric Association, 2021.
07: An HM, Tan YL, Shi J, et al. Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. Schizophr Res 2015;162(1-3):261-8. PMID 25600548
08: An HM, Tan YL, Shi J, et al. Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: possible involvement of S100B mechanisms. Behav Brain Res 2016;297:124-30. PMID 26455874
09: Anandan C, Jankovic J. Botulinum toxin in movement disorders: an update. Toxins (Basel) 2021;13(1):42. PMID 33430071
10: Ando K, Takei N, Matsumoto H, Iyo M, Isoda H, Mori N. Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophr Res 2002;57(2-3):273-9. PMID 12223259
11: Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jorgensen HA. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 2003;122:717-25. PMID 14622915
12: Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord 2014;20 Suppl 1:S113-7. PMID 24262160
13: Bergman J, Dwolatzky T, Brettholz I, Lerner V. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry 2005;66(1):107-10. PMID 15669896
14: Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011;87(1024):132-41. PMID 21131613
15: Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;81(5):463-9. PMID 23897874
16: Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci 2018;389:67-75. PMID 29454493
17: Bishnoi M, Chopra K, Kulkarni SK. Protective effect of curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav 2008;88(4):511-22. PMID 18022680
18: Bordia T, Zhang D, Perez XA, Quik M. Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia. Exp Neurol 2016;286:32-9. PMID 27658674
19: Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 2018;17(3):330-40. PMID 30192088
20: Caroff SN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 2001;62(10):772-5. PMID 11816865
21: Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61(Suppl 4):5-9. PMID 10739324
22: Chakrabarti S, Chand PK. Lithium-induced tardive dystonia. Neurol India 2002;50:473-5. PMID 12577099
23: Chang FC, Fung VS. Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. Pharmgenomics Pers Med 2014;7:317-28. PMID 25378945
24: Chong SA, Remington G, Mahendran R, Chua HC. Awareness of tardive dyskinesia in Asian patients with schizophrenia. J Clin Psychopharmacol 2001;21:235-7. PMID 11270922
25: Chong SA, Tan EC, Tan CH, Mythily S. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003;28:185-9. PMID 12790158
26: Citrome L. Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2017;71(11). PMID 29024264
27: Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001;62(12):967-74. PMID 11780878
28: Cowen MA, Green M, Bertollo DN, Abbott K. A treatment for tardive dyskinesia and some other extrapyramidal symptoms. J Clin Psychopharmacol 1997;17:190-3. PMID 9169964
29: D’Abreu A, Friedman J. Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov (n Y) 2018;8:570. PMID 30191087
30: De Risio L, Pettorruso M, Di Nicola M, Martinotti G, Janiri L, Fasano A. Management of aripiprazole-induced tardive Pisa syndrome: a case report and literature review. Int Clin Psychopharmacol 2016;31(1):57-60. PMID 26426442
31: Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003;53:1142-5. PMID 12814866
32: Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Arq Neuropsiquiatr 2004;62(3B):784-8. PMID 15476069
33: Factor SA. Propranolol therapy for tardive dyskinesia revisited. Mov Disord 2012;27(13):1703. PMID 23192928
34: Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry 1985;46(4 Pt 2):19-24. PMID 2858474
35: Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother 2009;10(17):2883-96. PMID 19929707
36: Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychosis. Acta Psychiatr Scand 1964;40:10-27. PMID 14217630
37: Fedorenko OY, Loonen AJ, Lang F, et al. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int J Neuropsychopharmacol 2014;18(6). PMID 25548108
38: Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003;9:16-27. PMID 12801428
39: Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry 2019;90(12):1317-23. PMID 31296586
40: Ford B, Greene P, Fahn S. Oral and genital tardive pain syndromes. Neurology 1994;44(11):2115-9. PMID 7969969
41: Fountoulakis KN, Samara M, Siapera M, Iacovides A. Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol 2011;26(5):237-42. PMID 21811171
42: Fox MD, Alterman RL. Brain stimulation for torsion dystonia. JAMA Neurol 2015;72(6):713-9. PMID 25894231
43: Frank S, Anderson KE, Fernandez HH, et al. Safety of deutetrabenazine for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Neurol Ther 2024;13(3):655-75. PMID 38557959
44: Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci 2018;389:10-6. PMID 29433810
45: Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153(12):1469-75. PMID 8512437
46: Garcia-Amador M, Merchan-Naranjo J, Tapia C, et al. Neurological adverse effects of antipsychotics in children and adolescents. J Clin Psychopharmacol 2015;35(6):686-93. PMID 26505569
47: Gardos G. Managing antipsychotic-induced tardive dyskinesia. Drug Saf 1999;20:187-93. PMID 10082074
48: Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994;151:836-41. PMID 7910437
49: Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32:692-8. PMID 9640489
50: Gittis AH, Leventhal DK, Fensterheim BA, Pettibone JR, Berke JD, Kreitzer AC. Selective inhibition of striatal fast-spiking interneurons causes dyskinesia. J Neurosci 2011;31(44):15727-31. PMID 22049415
51: Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K. Comparative analysis of Deutetrabenazine and Valbenazine as VMAT2 inhibitors for tardive dyskinesia: a systematic review. Tremor Other Hyperkinet Mov (N Y) 2024;14:13. PMID 38497033
52: Grabel M, Merola A. Pallidal deep brain stimulation for tardive dystonia: meta-analysis of clinical outcomes. Neurol Sci 2023;44(3):827-33. PMID 36378365
53: Halford J, Mazeika G, Slifer S, et al. APOE2 allele increased in tardive dyskinesia. Mov Disord 2006;21(4):540-2. PMID 16261623
54: Hardoy MC, Carta MG, Carpiniello B, et al. Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up. J Affect Disord 2003;75:125-30. PMID 12798252
55: Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA. Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonim Relat Disord 2016;32:124-6. PMID 27622970
56: Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: A 3-year, open-label extension study. Front Neurol 2022;13:773999. PMID 35280262
57: Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 2017;174(5):476-84. PMID 28320223
58: Hernandez G, Mahmoudi S, Cyr M, Diaz J, Blanchet PJ, Levesque D. Tardive dyskinesia is associated with altered putamen Akt/GSK-3b signaling in nonhuman primates. Mov Disord 2019;34(5):717-26. PMID 30675935
59: Hillier CE, Wiles CM, Simpson BA. Thalamotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiatry 1999;66:250-1. PMID 10071115
60: Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011;68(2):128-37. PMID 21300943
61: Huang CC, Wang RI, Hasegawa A, Alverno L. Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol Bull 1980;16(3):41-3. PMID 7403399
62: Iwata Y, Irie S, Uchida H, et al. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. J Neurol Sci 2012;315(1-2):137-40. PMID 22285275
63: Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 2016;17(18):2461-70. PMID 27819145
64: Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18(3):197-214. PMID 8635179
65: Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-62. PMID 9040721
66: Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 2011;11(11):1509-23. PMID 22014129
67: Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000;61(Suppl 4):27-32. PMID 10739328
68: Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington’s disease. Expert Opin Orphan Drugs 2013;1:423-36.
69: Johnsen M, Wester K. Full remission of tardive dyskinesia following general anaesthesia. J Neurol 2002;249(5):622-5. PMID 12021954
70: Kamyar M, Razavi BM, Hasani FV, Mehri S, Foroutanfar A, Hosseinsadeh H. Crocin prevents haloperidol-induced orofacial dyskinesia: possible an antioxidant mechanism. Iran J Basic Med Sci 2016;19(10):1070-9. PMID 27872703
71: Kane JM, Smith JM. Tardive dyskinesia; prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-81. PMID 6121548
72: Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22(1):254-8. PMID 2873613
73: Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1(3):193-208. PMID 2904118
74: Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6(1):7-17. PMID 16466307
75: Khedr EM, Al Fawal B, Abdelwarith A, Saber M, Rothwell JC. Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial. J Neural Transm (Vienna) 2019;126(2):183-91. PMID 30317532
76: Khot V, Egan MF, Hyde TM, Wyatt RJ. Neuroleptics and classic tardive dyskinesia. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mt. Kisco: Futura, 1992:121-66.
77: Kim J, Macmaster E, Schwartz TL. Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs Context 2014;3:212259. PMID 24744806
78: Kiriakakis V, Bhatia KP, Guinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121(Pt 11):2053-66. PMID 9827766
79: Klawans HL, Tanner CM, Barr A. The reversibility of "permanent" tardive dyskinesia. Clin Neuropharmacol 1984;7:153-9. PMID 6145520
80: Klawans HL, Tanner CM, Goetz CG. Epidemiology and pathophysiology of tardive dyskinesia. Adv Neurol 1988;49:185-97. PMID 2894124
81: Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord 2006;21(8):1219-21. PMID 16637037
82: Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry Suppl 1992;(17):38-40. PMID 1418887
83: Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today 2003;39:19-49. PMID 12669107
84: Kuo SH, Jankovic J. Tardive gait. Clin Neurol Neurosurg 2008;110(2);198-201. PMID 17997030
85: Lee D, Baek JH, Bae M, Choi Y, Hong KS. Long-term response to clozapine and its clinical correlates in the treatment of tardive movement syndromes: a naturalistic observational study in patients with psychotic disorders. J Clin Psychopharmacol 2019;39(6):591-6. PMID 31688397
86: Lee HJ, Kang SG. Genetics of tardive dyskinesia. Int Rev Neurobiol 2011;98:231-64. PMID 21907090
87: Lee MJ, Lin PY, Chang YY, Chong MY, Lee Y. Antipsychotics-induced tardive syndrome: a retrospective epidemiological study. Clin Neuropharmacol 2014;37(4):111-5. PMID 24992086
88: Lee Y, Lin PY, Chang YY, Chong MY, Cheng AT. Antidepressant-induced tardive syndrome: a retrospective epidemiological study. Pharmacopsychiatry 2013;46(7):281-5. PMID 24057776
89: Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27(1):105-19. PMID 12062911
90: Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci 2015;69(6):321-34. PMID 25556809
91: Levchenko A, Kanapin A, Samsonova A, et al. A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 2021;105:110134. PMID 33065217
92: LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol 2013;36(3):92-3. PMID 23673911
93: Lister J, Andreazza AC, Navaid B, et al. Lipoic acid and haloperidol-induced vacuous chewing movements: implications for prophylactic antioxidant use in tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 2017;72:23-9. PMID 27565433
94: Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA. The clinical challenges of akathisia. CNS Spectr 2015;20 Suppl 1:1-14; quiz 15-16. PMID 26683525
95: Loonen AJ, Wilffert B, Ivanova SA. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. Pharmacogenomics 2019;20(17):1199-223. PMID 31686592
96: Lv Z, Rong B, Tong X, et al. The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk. Int J Neurosci 2016;126(11):1044-50. PMID 26398367
97: Mahmoudi S, Lévesque D, Blanchet PJ. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord 2014;29(9):1125-33. PMID 24838395
98: Marder SR, Singer C, Lindenmayer JP, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol 2019;39(6):620-7. PMID 31688452
99: Matson JL, Fodstad JC, Neal D, Dempsey T, Rivet TT. Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use. Res Dev Disabil 2010;31(1):108-16. PMID 19720497
100: Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectr 2006;11(6):435-9. PMID 16816781
101: McCormick SE, Stoessl AJ. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience 2002;112:851-9. PMID 12088744
102: McCormick SE, Stoessl AJ. Central administration of the neurotensin receptor antagonist sr48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience 2003;119:547-55. PMID 12770567
103: McCreadie RG, Thara R, Srinivasan TN, Padmavathi R. Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia. Br J Psychiatry 2003;183:45-9. PMID 12835243
104: McGrath JJ, Soares KV. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2000;2:CD000459. PMID 10796546
105: Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord 2005;20(1):86-9. PMID 15390048
106: Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent in children. Expert Rev Neurother 2010;10(6):893-901. PMID 20518606
107: Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry 2012;73(11):1434-8. PMID 23218160
108: Mezzomo NF, da Silva Schmitz I, de Lima VB, et al. Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones. Mol Biol Rep 2022;49(3):1917-23. PMID 34854012
109: Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989;149(11):2486-92. PMID 2684075
110: Miodownik C, Cohen H, Kotler M, Lerner V. Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah 2003;142:592-6, 647. PMID 14518160
111: Morigaki R, Mure H, Kaji R, Nagahiro S, Goto S. Therapeutic perspective on tardive syndrome with special reference to deep brain stimulation. Front Psychiatry 2016;7:207. PMID 27565433
112: Muscettola G, Pampallona S, Barbato G, Casiello M, Bollini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand 1993;87:29-36. PMID 8093821
113: Niemann N, Jankovic J. Treatment of tardive dyskinesia; a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs 2018;78(5):525-41. PMID 29484607
114: O’Brien A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry 2016;31(7):683-93. PMID 26679687
115: O'Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 2015;30(12):1681-7. PMID 26346941
116: O'Callaghan E, Larkin C, Kinsella A, Waddington JL. Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia. Br J Psychiatry 1990;157:578-84. PMID 1983389
117: Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-81. PMID 10450276
118: Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003;64:1075-80. PMID 14628983
119: Ovsiew F, Meador KJ, Sethi K. Verapamil for severe hyperkinetic movement disorders. Mov Disord 1998;13:341-4. PMID 9539352
120: Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesias: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010;33(6):271-5. PMID 21121175
121: Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3(3):138-48. PMID 16511548
122: Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014;13(1):100-12. PMID 24331796
123: Patel RS, Mansuri Z, Chopra A. Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: a nationwide case-control study. Heliyon 2019;5(5):e01745. PMID 31193370
124: Quik M, Bordia T, Zhang D, Perez XA. Nicotine and nicotinic receptor drugs: potential for Parkinson's disease and drug-induced movement disorders. Int Rev Neurobiol 2015;124:247-71. PMID 26472532
125: Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011;26:147-52. PMID 20818603
126: Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 2016;86(7):651-9. PMID 26791148
127: Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31(1):11-9. PMID 19886950
128: Samad N, Haleem MA, Haleem DJ. Report: protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. Pak J Pharm Sci 2016;29(4 Suppl):1467-71. PMID 27592482
129: Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci 2018;389:35-42. PMID 29506749
130: Schaffer LF, de Freitas CM, Chiapinotto Ceretta AP, et al. Harpagophytum procumbens ethyl acetate fraction reduces fluphenazine-induced vacuous chewing movements and oxidative stress in rat brain. Neurochem Res 2016;41(5):1170-84. PMID 26732278
131: Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt 1957;28(12):550-3. PMID 13517450
132: Scorr LM, Factor SA. VMAT2 inhibitors for the treatment of tardive dyskinesia. J Neurol Sci 2018;389:43-7. PMID 29433808
133: Seeman P, Tinazzi M. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 2013;44:178-83. PMID 23454261
134: Selfani K, Soland VL, Chouinard S, Huot P. Movement disorders induced by the “atypical” antipsychotic aripiprazole. Neurologist 2017;22(1):24-8. PMID 28009769
135: Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Perinatol 1989;9:170-2. PMID 2738729
136: Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58(11):1049-52. PMID 11695951
137: Sharma VD, Gupta HV, Espay AJ. Copulatory dyskinesia: pathognomonic manifestation of tardive dyskinesia. Tremor Other Hyperkinet Mov (N Y) 2020;10:56. PMID 33362950
138: Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 2000;152:174-80. PMID 11057521
139: Soares-Weiser K, Fernandez HH. Tardive dyskinesias. Semin Neurol 2007;27(2):159-69. PMID 17390261
140: Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;2:CD000209. PMID 21328246
141: Srivastava V, Varma PG, Prasad S, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16(2):111-7. PMID 16424823
142: Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993;43(5):937-41. PMID 8492949
143: Sun B, Chen S, Zhan S, Le W, Krahl SE. Subthalamic nucleus stimulation for primary dystonia and tardive dystonia. Acta Neurochir Suppl 2007;97(Pt 2):207-14. PMID 17691306
144: Sunzel EM, Rabinovich-Guilatt L, Iyengar M, et al. A bioequivalence comparison between the once-daily extended-release tablet and the twice-daily tablet formulations of Deutetrabenazine at steady state. Clin Pharmacol Drug Dev 2024;13(3):224-32. PMID 38214040
145: Tan EC, Chong SA, Mahendran R, Dong F, Tan CH. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001;50(2):144-7. PMID 11526996
146: Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 2000;68:186-90. PMID 10644785
147: Tan YL, Zhou DF, Zhang XY. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2005;74(2-3):263-70. PMID 15722005
148: Tarsy D. Tardive dyskinesia. Curr Treat Options Neurol 2000;2:205-14. PMID 11096748
149: Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006;21(5):589-98. PMID 16532448
150: Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16(1):23-45. PMID 11772117
151: Tarsy D, Indorf G. Tardive tremor due to metoclopramide. Mov Disord 2002;17(3):620-1. PMID 12112224
152: Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 2012;27(10):1205-15. PMID 22865512
153: Tsermpini EE, Redenšek S, Dolžan V. Genetic factors associated with tardive dyskinesia: from pre-clinical models to clinical studies. Front Pharmacol 2022;12:834129. PMID 35140610
154: Vanegas-Arroyave N, Caroff SN, Citrome L, et al. An evidence-based update on anticholinergic use for drug-induced movement disorders. CNS Drugs 2024;38(4):239-54. PMID 38502289
155: van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord 2006;21(8):1276-7. PMID 16671083
156: Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013a;3. PMID 23858394
157: Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord 2013b;28(12):1748-9. PMID 23637028
158: Wang W, Du G, Lin S, et al. (+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a highly potent vesicular monoamine transporter 2 inhibitor for tardive dyskinesia. Front Pharmacol 2021a;12:770377. PMID 34950030
159: Wang MH, Yang CC, Tseng HC, Fang CH, Lin YW, Soung HS. Naringin ameliorates haloperidol-induced neurotoxicity and orofacial dyskinesia in a rat model of human tardive dyskinesia. Neurotox Res 2021b;39(3):774-86. PMID 33523404
160: Weetman J, Anderson JM, Gregory RP, Gill SS. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiatry 1997;63:554-6. PMID 9343153
161: Whitehorn D, Kopala LC. Neuromotor dysfunction in early psychosis. Ann Clin Psychiatry 2002;14(2):113-21. PMID 12238736
162: Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache 2016;56(1):153-61. PMID 26573884
163: Wong J, Pang T, Cheuk NKW, Liao Y, Bastiampillai T, Chan SKW. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders. Psychopharmacology (Berl) 2022;239(11):3393-420. PMID 36180741
164: Wu JQ, Chen da C, Tan YL, Soares JC, Zhang XY. Mn-superoxide dismutase activity is associated with orofacial involuntary movements in schizophrenia patients with tardive dyskinesia. Hum Psychopharmacol 2015;30(1):57-63. PMID 25572310
165: Xu H, Qin H, Chen S, Guan M. Vitamin E in the treatment of tardive dyskinesia: a meta-analysis. Int Clin Psychopharmacol 2022;37(2):60-6. PMID 35045531
166: Yassa R, Lal S. Respiratory irregularity and tardive dyskinesia. A prevalence study. Acta Psychiatr Scand 1986;73(5):506-10. PMID 2875609
167: Yu T, Li Y, Fan F, et al. Decreased gray matter volume of cuneus and lingual gyrus in schizophrenia patients with tardive dyskinesia is associated with abnormal involuntary movements. Sci Rep 2018;8(1):12884. PMID 30150749
168: Zhang JG, Zhang K, Wang ZC. Deep brain stimulation in the treatment of tardive dyskinesia. Chin Med J (Engl) 2006;119(9):789-92. PMID 16701024
169: Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, placebo-controlled trial. J Clin Psychiatry 2011;72(5):615-21. PMID 20868638
170: Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen da C, Wu GY. The effect of vitamin e treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol 2004;24:83-6. PMID 14709952
171: Zhang XY, Zhang WF, Zhou DF. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry 2012;72(8):700-6. PMID 22695185
172: Zhang Z, Zhang X, Hou G, Sha W, Reynolds GP. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002;36(5):317-24. PMID 12127599
173: Zhang ZJ, Zhang XB, Hou G, Yao H, Reynolds GP. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatr Genet 2003;13:187-92. PMID 12960753

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Olga Waln MD

Dr. Waln of Houston Methodist Neurological Institute has no relevant financial relationships to disclose.
See Profile

Editor

Robert Fekete MD

Dr. Fekete of New York Medical College received consultation fees from Acadia Pharmaceutical, Acorda, Adamas/Supernus Pharmaceuticals, Amneal/Impax, Kyowa Kirin, Lundbeck Inc., Neurocrine Inc., and Teva Pharmaceutical, Inc.
See Profile

Former Authors

David E Riley MD
Christopher J Kenney MD
Nelson Hwynn DO
Hubert H Fernandez MD
Mary Ann Thenganatt MD
Joseph Jankovic MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: female>male, >1:1
Heredity: Heredity might be a factor.
Population groups selectively affected: No population group selectively affected.
Occupation groups selectively affected: No occupation group selectively affected

ICD & OMIM codes

ICD-10: Orofacial dyskinesia: G24.4

Tardive dyskinesia: G24.0
ICD-11: Drug-induced dystonia: 8A02.10

Dystonia: MB47.4

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Tardive dyskinesia

Associated Disorders

Drug-induced parkinsonism
Drug-induced tremor

Differential Diagnosis

Chorea
Edentulous dyskinesias
Huntington disease
levodopa-induced dyskinesia

Also Relevant

Acute drug-induced movement disorders
Antipsychotics
Basal ganglia: functional anatomy and neuropharmacology
Blepharospasm
Botulinum toxin treatment of neurologic disorders
- Chorea
- Deep brain stimulation in movement disorders
- Drug-induced neurologic disorders
- Motor control of movement disorders
- Movement disorders in childhood
- Rating scales of movement disorders
- Stereotypies
- Tardive dystonia
- Vitamin E in neurologic disorders

Clinical Categories

Movement Disorders

Patient Handouts

Tardive dyskinesia

Web References

Clinical Trials

NIH: Chorea

	• Thorough review of medication history is crucial in establishing the diagnosis.
	• No ancillary testing is necessary for patients with characteristic clinical presentation.

Tardive dyskinesia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

This is an article preview.
Start a Free Account
to access the full version.